Bristol-myers Squibb Compnay

Zhengxiang Gu

Natesan Murugesan

William R Ewing

John E Macor

Bruce A Ellsworth

Chongqing Sun

Yanting Huang

Annapurna Pendri

Samuel Gerritz

Doree F Sitkoff

John E Tellew

Richard B Sulsky

Philip Michael Sher

Guixue Yu

Gang Wu

Amarendra B Mikkilineni

Ximao Wu

Ying Wang

Joel C Barrish

Gregory S Bisacchi

Minsheng Zhang

Jun Shi

Yeheng Zhu

Todd J Friends

Andres S Hernandez

Stephen P O'Connor

Zhenqiu Hong

Elizabeth Anne Jurica

Scott A Bolton

Leena Fadnis

Gergory S Bisacchi

Stephen R Johnson

Richard A Morrison

Stephen P O'CONNOR

The present invention provides compounds of Formula (I): (Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH, or CH; Z is CH or N; Rand Rare hydrogen or (C-C)alkyl; Ris (C-C)alkoxy, OH, CN, (C-C)alkyl, halogen, or CF; r and s are 0, 1, or 2; and Rand Rare as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor. 

Substituted adipic acid amides and uses thereof

The invention provides for compounds of formula I  Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

Tetrahydroquinoline derivatives as cannabinoid receptor modulators

The present invention provides inhibitors of 15-LO according to Formula I, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions. 

Inhibitors of 15-lipoxygenase

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R, R, R, Rand Rare described herein.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Azabicyclic heterocycles as cannabinoid receptor modulators

Compounds having the formula, enantiomers, diastereomers, solvates and salts thereof, where R, R, R, R, A, X, and J are described herein, are inhibitors of calcium channel function, and are useful in treating calcium channel-dependent disorders, including hypertension.

Dihydropyrimidone inhibitors of calcium channel function

The present invention relates to substituted dihydropyrimidine inhibitors of calcium channel function having formula I where A, a, J, R, RR, R, and R, are defined herein; pharmaceutical compositions comprising said compounds; and methods of treating calcium channel-dependent disorders, including hypertension.

Substituted dihydropyrimidine inhibitors of calcium channel function

Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.

Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists

The compounds N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-bi phenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methy l]-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide, and salts thereof, useful as endothelin antagonists.

Isoxazolyl endothelin antagonists

Growing community of inventors

Princeton, NJ, United States of America

Zhengxiang Gu